Target Name: FITM2
NCBI ID: G128486
Review Report on FITM2 Target / Biomarker Content of Review Report on FITM2 Target / Biomarker
FITM2
Other Name(s): DJ881L22.2 | fat-inducing protein 2 | Fat inducing transcript 2 | Acyl-coenzyme A diphosphatase FITM2 | Fat storage inducing transmembrane protein 2 | C20orf142 | fat-inducing transcript 2 | Fat-inducing protein 2 | SIDDIS | FITM2_HUMAN | Fat-inducing transcript 2 | dJ881L22.2 | Fat storage-inducing transmembrane protein 2 | Fit2 | fat storage inducing transmembrane protein 2

FITM2: A Potential Drug Target Or Biomarker for Neurodegenerative Diseases

FITM2 (DJ881L22.2), a protein found in various tissues including the brain, heart, and kidneys, is a potential drug target or biomarker in the field of neurodegenerative diseases. Its function and role in the development of these diseases have been studied extensively in recent years, and there is growing interest in using FITM2 as a therapeutic target.

FITM2 is a transmembrane protein that is expressed in a variety of tissues, including the brain, heart, and kidneys. Its primary function is to regulate the activity of the ion channels responsible for maintaining the electrical properties of these tissues. Specifically, FITM2 is involved in the regulation of sodium and potassium channels, which are critical for the proper functioning of these tissues.

One of the most significant aspects of FITM2's function is its role in the development of neurodegenerative diseases. As the number of cases of neurodegenerative diseases continues to rise, including Alzheimer's, Parkinson's, and Huntington's diseases, there is a growing need for new and effective treatments . FITM2 is thought to be a potential drug target or biomarker in these diseases, as its dysfunction or abnormalities may contribute to the development and progression of these conditions.

Studies have shown that FITM2 is involved in the development of neurodegenerative diseases in various experimental models, including mouse models of Alzheimer's and Parkinson's diseases. For example, researchers have found that overexpression of FITM2 in mouse models of Alzheimer's disease led to increased neurofibrillary tangles and decreased cognitive function, while inhibition of FITM2 did not protect against these effects. Similarly, in Parkinson's disease, FITM2 has been shown to be involved in the misfolding and aggregation of neurotransmitter-producing cells, which may contribute to the development and progression of the disease.

FITM2's role in neurodegenerative diseases is further supported by its expression in human brains and its association with the neurodegenerative diseases. Studies have shown that FITM2 is expressed in the brain and that its levels are reduced in individuals with neurodegenerative diseases. This suggests that FITM2 may be a useful biomarker or drug target in these diseases.

In addition to its potential role as a drug target or biomarker, FITM2 is also of interest in the context of neurodegenerative diseases because of its known effects on the electrical properties of various tissues. FITM2 is involved in the regulation of sodium and potassium channels, which are critical for maintaining the electrical integrity of these tissues. This suggests that alterations in FITM2's function may contribute to the disruption of electrical homeostasis, a hallmark feature of neurodegenerative diseases.

FITM2's potential as a drug target or biomarker in neurodegenerative diseases is an area of 鈥嬧?媜ngoing research, and there is a growing body of evidence to support its involvement in these conditions. Further studies are needed to fully understand the role of FITM2 in the development and progression of neurodegenerative diseases, as well as its potential as a therapeutic target or biomarker.

In conclusion, FITM2 (DJ881L22.2) is a protein that is expressed in various tissues and is involved in the regulation of the electrical properties of these tissues. Its function and role in the development of neurodegenerative diseases have been studied extensively in recent years, and there is growing interest in using FITM2 as a therapeutic target or biomarker. Further studies are needed to fully understand its involvement in these conditions and its potential as a drug.

Protein Name: Fat Storage Inducing Transmembrane Protein 2

Functions: Fatty acyl-coenzyme A (CoA) diphosphatase that hydrolyzes fatty acyl-CoA to yield acyl-4'-phosphopantetheine and adenosine 3',5'-bisphosphate (PubMed:32915949) (By similarity). Preferentially hydrolyzes unsaturated long-chain acyl-CoA substrates such as oleoyl-CoA/(9Z)-octadecenoyl-CoA and arachidonoyl-CoA/(5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA in the endoplasmic reticulum (ER) lumen (PubMed:32915949) (By similarity). This catalytic activity is required for maintaining ER structure and for lipid droplets (LDs) biogenesis, which are lipid storage organelles involved in maintaining lipid and energy homeostasis (PubMed:18160536, PubMed:32915949) (By similarity). Directly binds to diacylglycerol (DAGs) and triacylglycerol, which is also important for LD biogenesis (By similarity). May support directional budding of nacent LDs from the ER into the cytosol by reducing DAG levels at sites of LD formation (By similarity). Plays a role in the regulation of cell morphology and cytoskeletal organization (PubMed:21834987) (By similarity)

The "FITM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FITM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Five friends of methylated CHTOP complex | FIZ1 | FJX1 | FKBP10 | FKBP11 | FKBP14 | FKBP15 | FKBP1A | FKBP1A-SDCBP2 | FKBP1B | FKBP1C | FKBP2 | FKBP3 | FKBP4 | FKBP5 | FKBP6 | FKBP7 | FKBP8 | FKBP9 | FKBP9P1 | FKBPL | FKRP | FKSG29 | FKTN | FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P | FMO9P | FMOD | FMR1 | FMR1-AS1 | FMR1NB | FN1 | FN3K | FN3KRP | FNBP1 | FNBP1L | FNBP1P1 | FNBP4